

## Documents

Mannucci, P.M.<sup>a</sup>, Hermans, C.<sup>b</sup>

**Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries**

(2024) *Haemophilia*, 30 (3), pp. 575-576. Cited 2 times.

**DOI:** 10.1111/hae.14968

<sup>a</sup> Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

<sup>b</sup> Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

**Author Keywords**

emicizumab; humanitarian aid program; low income countries

**Index Keywords**

blood clotting factor 8, emicizumab, bispecific antibody, emicizumab, monoclonal antibody; clinical outcome, clinical protocol, drug efficacy, drug monitoring, drug safety, health care access, hemophilia A, hemophilia B, human, low drug dose, low income country, middle income country, Note, pharmacovigilance, prophylaxis, steady state, developed country, health care access; Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Developing Countries, Health Services Accessibility, Hemophilia A, Humans

**Correspondence Address**

Mannucci P.M.; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; email: piermannuccio.mannucci@policlinico.mi.it

**Publisher:** John Wiley and Sons Inc

**ISSN:** 13518216

**CODEN:** HAEMF

**PubMed ID:** 38415381

**Language of Original Document:** English

**Abbreviated Source Title:** Haemophilia

2-s2.0-85186601711

**Document Type:** Note

**Publication Stage:** Final

**Source:** Scopus